1035 related articles for article (PubMed ID: 33189888)
21. Off-label tocilizumab and adjuvant iron chelator effectiveness in a group of severe COVID-19 pneumonia patients: A single center experience.
Birlutiu V; Birlutiu RM; Chicea L
Medicine (Baltimore); 2021 May; 100(18):e25832. PubMed ID: 33950993
[TBL] [Abstract][Full Text] [Related]
22. High Induction of IL-6 Secretion From hUCMSCs Optimize the Potential of hUCMSCs and TCZ as Therapy for COVID-19-Related ARDS.
Lo HY; Cheng SP; Huang JL; Chang KT; Chang YL; Huang CH; Chang CJ; Chiu CH; Chen-Yang YW; Chan CK
Cell Transplant; 2021; 30():9636897211054481. PubMed ID: 34757857
[TBL] [Abstract][Full Text] [Related]
23. Tocilizumab Treatment for Cytokine Release Syndrome in Hospitalized Patients With Coronavirus Disease 2019: Survival and Clinical Outcomes.
Price CC; Altice FL; Shyr Y; Koff A; Pischel L; Goshua G; Azar MM; Mcmanus D; Chen SC; Gleeson SE; Britto CJ; Azmy V; Kaman K; Gaston DC; Davis M; Burrello T; Harris Z; Villanueva MS; Aoun-Barakat L; Kang I; Seropian S; Chupp G; Bucala R; Kaminski N; Lee AI; LoRusso PM; Topal JE; Dela Cruz C; Malinis M
Chest; 2020 Oct; 158(4):1397-1408. PubMed ID: 32553536
[TBL] [Abstract][Full Text] [Related]
24. Randomized, double-blind, controlled trial of human anti-LIGHT monoclonal antibody in COVID-19 acute respiratory distress syndrome.
Perlin DS; Neil GA; Anderson C; Zafir-Lavie I; Raines S; Ware CF; Wilkins HJ
J Clin Invest; 2022 Feb; 132(3):. PubMed ID: 34871182
[TBL] [Abstract][Full Text] [Related]
25. Efficacy of Tocilizumab Therapy in Different Subtypes of COVID-19 Cytokine Storm Syndrome.
Oliynyk O; Barg W; Slifirczyk A; Oliynyk Y; Gurianov V; Rorat M
Viruses; 2021 Jun; 13(6):. PubMed ID: 34205217
[TBL] [Abstract][Full Text] [Related]
26. Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial.
Declercq J; Van Damme KFA; De Leeuw E; Maes B; Bosteels C; Tavernier SJ; De Buyser S; Colman R; Hites M; Verschelden G; Fivez T; Moerman F; Demedts IK; Dauby N; De Schryver N; Govaerts E; Vandecasteele SJ; Van Laethem J; Anguille S; van der Hilst J; Misset B; Slabbynck H; Wittebole X; Liénart F; Legrand C; Buyse M; Stevens D; Bauters F; Seys LJM; Aegerter H; Smole U; Bosteels V; Hoste L; Naesens L; Haerynck F; Vandekerckhove L; Depuydt P; van Braeckel E; Rottey S; Peene I; Van Der Straeten C; Hulstaert F; Lambrecht BN
Lancet Respir Med; 2021 Dec; 9(12):1427-1438. PubMed ID: 34756178
[TBL] [Abstract][Full Text] [Related]
27. Tocilizumab therapy for severely-ill COVID-19 pneumonia patients: a single-centre retrospective study.
Iqtadar S; Khan A; Mumtaz SU; Pascual-Figal DA; Livingstone S; Abaidullah S
J Physiol Pharmacol; 2022 Aug; 73(4):. PubMed ID: 36696245
[TBL] [Abstract][Full Text] [Related]
28. Therapeutic Role of Tocilizumab in SARS-CoV-2-Induced Cytokine Storm: Rationale and Current Evidence.
Pelaia C; Calabrese C; Garofalo E; Bruni A; Vatrella A; Pelaia G
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33802761
[TBL] [Abstract][Full Text] [Related]
29. Cytokine Profiles Before and After Immune Modulation in Hospitalized Patients with COVID-19.
Azmy V; Kaman K; Tang D; Zhao H; Dela Cruz C; Topal JE; Malinis M; Price CC
J Clin Immunol; 2021 May; 41(4):738-747. PubMed ID: 33459964
[TBL] [Abstract][Full Text] [Related]
30. Artificial intelligence assessment of the potential of tocilizumab along with corticosteroids therapy for the management of COVID-19 evoked acute respiratory distress syndrome.
Segú-Vergés C; Artigas L; Coma M; Peck RW
PLoS One; 2023; 18(2):e0280677. PubMed ID: 36791125
[TBL] [Abstract][Full Text] [Related]
31. COVID-19: Consider IL-6 receptor antagonist for the therapy of cytokine storm syndrome in SARS-CoV-2 infected patients.
Chakraborty C; Sharma AR; Bhattacharya M; Sharma G; Lee SS; Agoramoorthy G
J Med Virol; 2020 Nov; 92(11):2260-2262. PubMed ID: 32462717
[TBL] [Abstract][Full Text] [Related]
32. Clinical characteristics and predictors of survival in adults with coronavirus disease 2019 receiving tocilizumab.
Morrison AR; Johnson JM; Griebe KM; Jones MC; Stine JJ; Hencken LN; To L; Bianchini ML; Vahia AT; Swiderek J; Ramesh MS; Peters MA; Smith ZR
J Autoimmun; 2020 Nov; 114():102512. PubMed ID: 32646770
[TBL] [Abstract][Full Text] [Related]
33. A Perspective on Erythropoietin as a Potential Adjuvant Therapy for Acute Lung Injury/Acute Respiratory Distress Syndrome in Patients with COVID-19.
Sahebnasagh A; Mojtahedzadeh M; Najmeddin F; Najafi A; Safdari M; Rezai Ghaleno H; Habtemariam S; Berindan-Neagoe I; Nabavi SM
Arch Med Res; 2020 Oct; 51(7):631-635. PubMed ID: 32863034
[TBL] [Abstract][Full Text] [Related]
34. Efficacy of Tocilizumab in COVID-19: Single-Center Experience.
Kaya S; Kavak S
Biomed Res Int; 2021; 2021():1934685. PubMed ID: 34977235
[TBL] [Abstract][Full Text] [Related]
35. Tocilizumab as a Treatment for 'Cytokine Storm Syndrome' in COVID-19: A Case Report.
Syam AF; Pitoyo CW; Suhendro S; Zulkarnain B; Indrasari ND; Aditianingsih D; Irawan C; Susilo A; Rumende CM; Wijaya IP; Ibrahim F; Rasmin M; Alwi I; Makmun D
Acta Med Indones; 2021 Apr; 53(2):194-201. PubMed ID: 34251348
[TBL] [Abstract][Full Text] [Related]
36. IL-6 trans-signaling induces plasminogen activator inhibitor-1 from vascular endothelial cells in cytokine release syndrome.
Kang S; Tanaka T; Inoue H; Ono C; Hashimoto S; Kioi Y; Matsumoto H; Matsuura H; Matsubara T; Shimizu K; Ogura H; Matsuura Y; Kishimoto T
Proc Natl Acad Sci U S A; 2020 Sep; 117(36):22351-22356. PubMed ID: 32826331
[TBL] [Abstract][Full Text] [Related]
37. Divergent impacts of tocilizumab and colchicine in COVID-19-associated coagulopathy: the role of alpha-defensins.
Abdeen S; Abu-Fanne R; Bdeir K; Maraga E; Higazi M; Cines DB; Heyman SN; Higazi AA
Br J Haematol; 2022 Feb; 196(4):923-927. PubMed ID: 34622440
[TBL] [Abstract][Full Text] [Related]
38. The Role of Tocilizumab in Cytokine Storm and Improving Outcomes in COVID-19.
Ali A; Kamjani MH; Kesselman MM
Recent Pat Antiinfect Drug Discov; 2020; 15(2):104-112. PubMed ID: 32962623
[TBL] [Abstract][Full Text] [Related]
39. Tocilizumab in patients with severe COVID-19: A single-center observational analysis.
Knorr JP; Colomy V; Mauriello CM; Ha S
J Med Virol; 2020 Nov; 92(11):2813-2820. PubMed ID: 32628003
[TBL] [Abstract][Full Text] [Related]
40. Clinical outcomes in COVID-19 patients treated with tocilizumab: An individual patient data systematic review.
Antwi-Amoabeng D; Kanji Z; Ford B; Beutler BD; Riddle MS; Siddiqui F
J Med Virol; 2020 Nov; 92(11):2516-2522. PubMed ID: 32436994
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
